Home/Pipeline/OMN-001

OMN-001

Mucopolysaccharidosis type I

PreclinicalActive

Key Facts

Indication
Mucopolysaccharidosis type I
Phase
Preclinical
Status
Active
Company

About Omnes Therapeutics

A Belgian AAV‑based gene‑therapy platform targeting rare metabolic diseases.

View full company profile

Therapeutic Areas